Prolonged rapid eye movement (REM) sleep latency was linked with Alzheimer's disease biomarkers, cross-sectional data showed.

17 clinical scenarios developed for which amyloid or tau PET may be considered. (HealthDay News) — Appropriate use criteria (AUC) for the use of amyloid and tau positron emission tomography (PET ...

The pathological hallmarks of AD are amyloid plaques and neurofibrillary tangles in the brain ... (2014) found that UCHL1 was one target of miR-922, and the phosphorylation levels of Tau were ...

17 clinical scenarios were developed for which amyloid or tau PET may be considered. Gil D. Rabinovici, M.D., from the University of California San Francisco, and colleagues updated AUC for ...

This line of inquiry follows animal model and stem cell studies in which efavirenz reduced the accumulation of both amyloid beta and tau. It’s hypothesized that accumulation of cholesterol in ...

Background and Objective: Cerebral amyloid angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage and cognitive dysfunction in the elderly, and frequently coexists with Alzheimer’s ...

The revised criteria offer guidance for clinicians to determine when amyloid and tau PET are recommended. Criteria were divided into 17 common clinical scenarios with three subcategories of ...

Recent approvals by the Food and Drug Administration have focused on medications that shrink the sticky brain deposits of a protein called amyloid beta. The errant growth of this protein is ...

including β-amyloid deposits and amyloid plaques, neuritic dystrophy, astrogliosis, reactive microgliosis and abnormal tau phosphorylation 13,14,15. In additional to structural and neurochemical ...

“The discovery that tau phosphorylation can act as a protective ... investigate other pathogens that might interact with tau (or [beta-amyloid]) in Alzheimer’s, and test potential therapies ...